Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 126

Sort by

Sort Order Select

Journal Articles

Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly-Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) As Personalized Maintenance Therapy in Acute Myeloid Leukemia: First Results from a Phase 1b Study

Alexandre Bazinet, Hagop M. Kantarjian, Farhad Ravandi, Nicholas J. Short, Naval Daver, Maro Ohanian, Musa Yilmaz, Kelly S. Chien, Abhishek Maiti, Courtney D. DiNardo, Jo Ishizawa, Lucia Masarova, Debra Bull-Linderman, Gautam Borthakur, Elias Jabbour, Guillermo Garcia-Manero, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 2909.

https://doi.org/10.1182/blood-2023-172883

Published: 2023

Journal Articles

Azacitidine Plus Venetoclax Maintenance in Acute Myeloid Leukemia Produces Sustained Remissions with Low Toxicity: Results of a Phase 2 Study

Blood (2023) 142 (Supplement 1): 2884.

https://doi.org/10.1182/blood-2023-172882

Published: 2023

Journal Articles

A Phase II Study of Low-Intensity Chemotherapy (Mini-Hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 2868.

https://doi.org/10.1182/blood-2023-182997

Published: 2023

Journal Articles

A Phase 2 Study of the Fully Oral Combination of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax for Older and/or Unfit Patients with Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 833.

https://doi.org/10.1182/blood-2023-172658

Published: 2023

Journal Articles

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Blood (2023) 142 (Supplement 1): 158.

https://doi.org/10.1182/blood-2023-186699

Published: 2023

Journal Articles

Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Blood (2023) 142 (Supplement 1): 58.

https://doi.org/10.1182/blood-2023-182337

Published: 2023

Journal Articles

A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)

Robert Briski, Nicholas J. Short, Naval Daver, Tapan M. Kadia, Courtney D. DiNardo, Musa Yilmaz, Yesid Alvarado Valero, Kenneth Vaughan, Sherry Pierce, Kathryn Montalbano, Jillian Mullin, Hagop M. Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi

Blood (2023) 142 (Supplement 1): 2910.

https://doi.org/10.1182/blood-2023-187429

Published: 2023

Journal Articles

Updated Results from a Phase II Study of Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia

Daniel Nguyen, Hagop M. Kantarjian, Nicholas J. Short, Nitin Jain, Fadi G. Haddad, Musa Yilmaz, Alessandra Ferrajoli, Tapan M. Kadia, Yesid Alvarado Valero, Abhishek Maiti, Cedric Nasnas, Lewis Nasr, Rebecca Garris, Marina Y. Konopleva, Farhad Ravandi, Elias Jabbour

Blood (2023) 142 (Supplement 1): 4245.

https://doi.org/10.1182/blood-2023-190902

Published: 2023

Journal Articles

Mutational and Cytogenetic Dynamics at Diagnosis and Relapse in Acute Myeloid Leukemia: Influence of Intensity and Type of Treatment

Alex Bataller, Hagop M. Kantarjian, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Gautam Borthakur, Nicholas J. Short, Musa Yilmaz, Ghayas C. Issa, Yesid Alvarado Valero, Guillermo Montalban-Bravo, Abhishek Maiti, Hussein A Abbas, Elias Jabbour, William G. Wierda, Guillermo Garcia-Manero, Farhad Ravandi

Blood (2023) 142 (Supplement 1): 723.

https://doi.org/10.1182/blood-2023-179876

Published: 2023

Journal Articles

Update of a Phase II Trial of Guadecitabine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Under the International Working Group 2023 Criteria

Samuel Urrutia, Kelly S. Chien, Ziyi Li, Gautam Borthakur, Yesid Alvarado Valero, Tapan M. Kadia, Steven M. Kornblau, Naval Daver, Farhad Ravandi, Prithviraj Bose, Musa Yilmaz, Maro Ohanian, Rashmi Kanagal-Shamanna, Carlos E. Bueso-Ramos, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 1877.

https://doi.org/10.1182/blood-2023-184690

Published: 2023

Journal Articles

A Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Blood (2023) 142 (Supplement 1): 322.

https://doi.org/10.1182/blood-2023-190693

Published: 2023

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Blood (2023) 142 (Supplement 1): 4635.

https://doi.org/10.1182/blood-2023-189711

Published: 2023

Journal Articles

Patterns of Relapse in Patients with Acute Myeloid Leukemia (AML) Treated with Venetoclax-Containing Regimens

Naszrin Arani, Emmanuel Almanza, Alex Bataller, Courtney D. DiNardo, Farhad Ravandi, Naval Daver, Naveen Pemmaraju, Musa Yilmaz, Abhishek Maiti, Patrick K Reville, Sanam Loghavi, Hussein A Abbas, Guillermo Garcia-Manero, Nicholas J. Short, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4236.

https://doi.org/10.1182/blood-2023-191181

Published: 2023

Journal Articles

Cladribine-Based Chemotherapy for Patients with Secondary Acute Myeloid Leukemia (AML) Arising after Myeloproliferative Neoplasms (MPNs)

Lucia Masarova, Hagop M. Kantarjian, Naveen Pemmaraju, Hussein A Abbas, Prithviraj Bose, Mahesh Swaminathan, Sherry Pierce, Koji Sasaki, Musa Yilmaz, Nicholas J. Short, Naval Daver, Gautam Borthakur, Guillermo Garcia-Manero, Maro Ohanian, Kapil N. Bhalla, Courtney D. DiNardo, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4264.

https://doi.org/10.1182/blood-2023-187968

Published: 2023

Journal Articles

Poor Outcome of Patients with Acute Myeloid Leukemia in First Relapse Underscores the Need for Effective Initial Treatment

Blood (2023) 142 (Supplement 1): 1480.

https://doi.org/10.1182/blood-2023-179245

Published: 2023

Journal Articles

Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results

Georgina Gener-Ricos, Gautam Borthakur, Koji Sasaki, Guilin Tang, Guillermo Montalban-Bravo, Elias Jabbour, Maro Ohanian, Musa Yilmaz, Fadi G. Haddad, Kelly S. Chien, Jo Ishizawa, Nicholas J. Short, Abhishek Maiti, Mahesh Swaminathan, Guillermo Garcia-Manero, Naval Daver, Courtney D. DiNardo, Farhad Ravandi, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 2903.

https://doi.org/10.1182/blood-2023-187795

Published: 2023

Journal Articles

Single-Cell Proteomic Interrogation of FLT3-ITD Leukemia Compartment Revealsdistinct Leukemia Cell Populations Resistant to Quizartinib, Decitabine and Venetoclax

Muharrem Muftuoglu, Musa Yilmaz, Mahesh Basyal, Li Li, Takahiko Seki, Arnaud Lesegretain, Naval Daver, Michael Andreeff

Blood (2022) 140 (Supplement 1): 2273–2274.

https://doi.org/10.1182/blood-2022-171124

Published: 2022

Journal Articles

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML

Blood (2022) 140 (Supplement 1): 141–144.

https://doi.org/10.1182/blood-2022-170188

Published: 2022

Journal Articles

Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission

Blood (2022) 140 (Supplement 1): 543–545.

https://doi.org/10.1182/blood-2022-156955

Published: 2022

Journal Articles

Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Blood (2022) 140 (Supplement 1): 1702–1704.

https://doi.org/10.1182/blood-2022-167931

Published: 2022

NARROW

Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly-Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) As Personalized Maintenance Therapy in Acute Myeloid Leukemia: First Results from a Phase 1b Study

Azacitidine Plus Venetoclax Maintenance in Acute Myeloid Leukemia Produces Sustained Remissions with Low Toxicity: Results of a Phase 2 Study

A Phase II Study of Low-Intensity Chemotherapy (Mini-Hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

A Phase 2 Study of the Fully Oral Combination of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax for Older and/or Unfit Patients with Acute Myeloid Leukemia

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)

Updated Results from a Phase II Study of Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia

Mutational and Cytogenetic Dynamics at Diagnosis and Relapse in Acute Myeloid Leukemia: Influence of Intensity and Type of Treatment

Update of a Phase II Trial of Guadecitabine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Under the International Working Group 2023 Criteria

A Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Patterns of Relapse in Patients with Acute Myeloid Leukemia (AML) Treated with Venetoclax-Containing Regimens

Cladribine-Based Chemotherapy for Patients with Secondary Acute Myeloid Leukemia (AML) Arising after Myeloproliferative Neoplasms (MPNs)

Poor Outcome of Patients with Acute Myeloid Leukemia in First Relapse Underscores the Need for Effective Initial Treatment

Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results

Single-Cell Proteomic Interrogation of FLT3-ITD Leukemia Compartment Revealsdistinct Leukemia Cell Populations Resistant to Quizartinib, Decitabine and Venetoclax

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML

Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission

Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only